Pfizer Tasks “Established Products Unit” With Extending Life Of Mature Drugs
Executive Summary
As Pfizer faces a future without several key blockbuster drugs, Lipitor among them, the company is setting out to extend the life of its mature franchises with the formation of a dedicated business unit for established brands
You may also be interested in...
Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
The acquisition of Solvay's pharmaceutical unit, completed in February, gave Abbott a substantial branded generics business and strengthened its international presence. Now the company is looking to build on those assets with an enhanced emerging market strategy
Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.
GSK Takes Pay-As-You Go Approach In Aspen Branded Generics Deal
GlaxoSmithKline's licensing deal with South Africa-based branded generics drug maker Aspen is illustrative of the company's approach to acquisitions under new CEO Andrew Witty